

# MD Anderson at the 2024 ASCO Annual Meeting

THE UNIVERSITY OF TEXAS  
**MDAnderson  
Cancer Center**  
Making Cancer History®

[MDAnderson.org/ASCO](https://MDAnderson.org/ASCO)

All times are listed in Central Time. As of May 13.

Friday, May 31			
1-2:15 p.m.	Education Session	Germline Predisposition in Hematologic Malignancies: Testing, Management and Implications	E450b   On Demand
1:30-1:45 p.m.	Testing for Hereditary Hematologic Malignancies and Recommended Surveillance in Patients and Family Members		Courtney DiNardo, M.D.
1-2:30 p.m.	Education Session	New Drugs in Oncology: Incorporation into Practice	Arie Crown Theater   Live Stream
1:45-1:55 p.m.	Belzutifan for Advanced Renal Cell Carcinoma		Eric Jonasch, M.D.
2:45-4:15 p.m.	Rapid Oral Abstract Session	Breast Cancer—Local/Regional/Adjuvant	E451   On Demand
	Chair/Moderator		Puneet Singh, M.D.
2:45-5:45 p.m.	Oral Abstract Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	S100bc   Live Stream
3:57-4:09 p.m.	Abstract 6504: Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX Phase Ib/II study.		Elias Jabbour, M.D.
4:57-5:09 p.m.	Abstract 6507: A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.		Alexandre Bazinet, M.D.
2:45-5:45 p.m.	Oral Abstract Session	Melanoma/Skin Cancers	Hall D1   Live Stream
5:09-5:21 p.m.	Abstract 9508: Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti-PD-1 therapy.		Sapna Patel, M.D.
4:30-5:45 p.m.	Education Session	Contemporary Approach to Malignant Peripheral Nerve Sheath Tumors	102   On Demand
4:45-5 p.m.	The Biology of Malignant Peripheral Nerve Sheath Tumors		Alexander Lazar, M.D., Ph.D.
Saturday, June 1			
8-9:30 a.m.	Rapid Oral Abstract Session	Gynecologic Cancer	E451   On Demand
	Chair/Moderator		Anuja Jhingran, M.D.
8-9:30 a.m.	Rapid Oral Abstract Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant	E450b   On Demand
8-8:06 a.m.	Abstract 6509: Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase II results from the ASTREON trial.		Guillermo Garcia-Manero, M.D.
8:12-8:18 a.m.	Abstract 6511: Interim safety and efficacy of BP1001 in a Phase II acute myeloid leukemia (AML) study.		Maro Ohanian, D.O.
8:42-8:48 a.m.	Abstract 6514: Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib.		Julie Braish
9:06-9:12 a.m.	Abstract 6516: Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation.		Partow Kebriaei, M.D.

8-9:30 a.m.	Rapid Oral Abstract Session	Prevention, Risk Reduction, and Genetics	S402   On Demand
	Chair/Moderator	Abenaa Brewster, M.D.	
8-9:30 a.m.	Special Sessions	Using “Artificial” Intelligence to Achieve “Real” Improvements in Cancer Care	Hall D1   Live Stream
	Chair/Moderator		Caroline Chung, M.D.
9 a.m.-12 p.m.	Poster Sessions	Care Delivery/Models of Care Central Nervous System Tumors Developmental Therapeutics— Immunotherapy Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	Hall A   On Demand
	See the full listing of posters from MD Anderson starting on page 6.		
1:15-2:15 p.m.	Case-Based Panel	Follicular Lymphoma: A Case-Based Exploration of Treatment Choices and Management	S103   On Demand
	Moderator		Loretta Nastoupil, M.D.
1:15-2:30 p.m.	Education Session	Exploring Novel Therapeutic Approaches to Cancer Prevention: Vaccines and Beyond	S402   On Demand
1:30-1:45 p.m.	Prevention Strategies for Patients With Lynch Syndrome		Eduardo Vilar Sanchez, M.D., Ph.D.
2-2:30 p.m.	Moderator		
1:15-2:45 p.m.	Clinical Science Symposium	Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum	E451   On Demand
2:15-2:27 p.m.	Discussion of Abstract 5511: Borrowing From Breast Cancer: Endocrine Combinations in Endometrial Cancer		Lauren Cobb, M.D.
1:30-4:30 p.m.	Poster Sessions	Gastrointestinal Cancer—Colorectal and Anal Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Melanoma/Skin Cancers Pediatric Oncology Sarcoma	Hall A   On Demand
	See the full listing of posters from MD Anderson starting on page 6.		
3-6 p.m.	Oral Abstract Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	Hall D1   Live
3-3:12 p.m.	Abstract 3000: First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).		Scott Kopetz, M.D., Ph.D.
4:12-4:24 p.m.	Abstract 3005: First-in-human Phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.		Timothy Yap, M.B.B.S., Ph.D.
3-6 p.m.	Oral Abstract Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	S100bc   Live Stream
5:12-5:24 p.m.	Abstract 7007: Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.		Michael Wang, M.D.
4:30-6 p.m.	Rapid Oral Abstract Session	Lung Cancer—Non-Small Cell Metastatic	S406   On Demand
	Chair/Moderator		Natalie Vokes, M.D.
4:36-4:42 p.m.	Abstract 8514: Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.		John Heymach, M.D., Ph.D.

4:45-6 p.m.	Education Session	Navigating the Complexities of Brain Metastases Management	E450a   On Demand
5-5:15 p.m.	Immunotherapy and Beyond: Advances in Systemic Therapy for Patients With Melanoma and Brain Metastases		Hussein Tawbi, M.D., Ph.D.
<b>Sunday, June 2</b>			
8-9:15 a.m.	Education Session	New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer	S406   On Demand
8:30-8:45 a.m.	Incorporating Tyrosine Kinase Inhibitors Into Early-Stage Lung Cancer		Xiuning Le, M.D., Ph.D.
8:45-9:15 a.m.	Panel Question and Answer		
8-11 a.m.	Oral Abstract Session	Gynecologic Cancer	Hall D2   Live Stream
9:12-9:24 a.m.	Abstract 5504: Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.		Anuja Jhingran, M.D.
10-10:12 a.m.	Panel Question and Answer		
8:15-9:30 a.m.	Highlights of the Day Session	Highlights of the Day I	Hall D1   Live Stream
9-9:15 a.m.	Genitourinary Cancer—Prostate, Testicular, and Penile		Andrew Hahn, M.D.
9 a.m.-12 p.m.	Poster Sessions	Breast Cancer—Local/Regional/Adjuvant Breast Cancer—Metastatic Genitourinary Cancer—Kidney and Bladder Genitourinary Cancer—Prostate, Testicular, and Penile Head and Neck Cancer	Hall A   On Demand
		See the full listing of posters from MD Anderson starting on page 6.	
9:45-11 a.m.	Education Session	Exploring the Spectrum of Inherited Cancer Susceptibility: Genetics, Risk Factors, and Prevention Strategies	S402   On Demand
10-10:15 a.m.	Moderate Penetrance Cancer Susceptibility Genes for Breast Cancer Risk: Managing the Gray Areas		Banu Arun, M.D.
10:30-11 a.m.	Panel Question and Answer		
11:30 a.m.-1 p.m.	Clinical Science Symposium	Can Predictive Markers Help Us Risk-Stratify Patients With Sarcoma?	S402   On Demand
12:18-12:30 p.m.	Abstract 11511: Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes.		Ryan Denu, M.D., Ph.D.
12:42-1 p.m.	Panel Question and Answer		
11:30-1 p.m.	Rapid Oral Abstract Session	Central Nervous System Tumors	E350   On Demand
12:12-12:18 p.m.	Abstract 2018: Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 Phase II study results.		Barbara O'Brien, M.D.
12:18-12:30 p.m.	Panel Question and Answer		
11:30-1 p.m.	Rapid Oral Abstract Session	Central Nervous System Tumors	S406   On Demand
12:06-12:12 p.m.	Abstract 2517: Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis.		Yinghong Wang, M.D., Ph.D.
12:18-12:30 p.m.	Panel Question and Answer		
1-4 p.m.	Plenary Session		Hall B1   Live Stream
3:33-3:45 p.m.	Discussion of LBA5: ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).		Lauren Averett Byers, M.D.,
3:45-3:55 p.m.	Panel Question and Answer		
4:30-6 p.m.	Rapid Oral Abstract Session	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	E450b   On Demand

4:30-4:36 p.m.	Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the Phase II CAPTIVATE study.		William Wierda, M.D., Ph.D.
4:48-5 p.m.	Panel Question and Answer		
4:30-6 p.m.	Rapid Oral Abstract Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	S406   On Demand
4:36-4:42 p.m.	Abstract 8011: Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN.		John Heymach, M.D., Ph.D.
4:48-5 p.m.	Panel Question and Answer		
<b>Monday, June 3</b>			
8-9:30 a.m.	Rapid Oral Abstract Session	Head and Neck Cancer	E450b   On Demand
	Chair/Moderator		Renata Ferrarotto, M.D.
8:36-8:42 a.m.	Abstract 6016: Intralesional nivolumab in oral potentially malignant disorders: A Phase I pilot study on safety, tolerability, and preliminary efficacy.		Shorook Naara, M.D., Ph.D.
8:48-9 a.m.	Panel Question and Answer		
8-9:30 a.m.	Rapid Oral Abstract Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	S406   On Demand
	Chair/Moderator		Ecaterina Elena Dumbrava, M.D.
9-9:06 a.m.	Abstract 3018: A Phase I study of highly potent oral ATR inhibitor (ATRI) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.		Timothy Yap, M.D., Ph.D.
9:18-9:30 a.m.	Panel Question and Answer		
8-11 a.m.	Oral Abstract Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Arie Crown Theater   Live Stream
10-10:12 a.m.	Abstract LBA8007: Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the Phase III CheckMate 77T study.		Tina Cascone, M.D., Ph.D.
10:48-11 a.m.	Panel Question and Answer		
9 a.m.-12 p.m.	Poster Session	Gynecologic Cancer Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Hematologic Malignancies—Plasma Cell Dyscrasia Quality Care/Health Services Research	Hall A   On Demand
<b>See the full listing of posters from MD Anderson starting on page 6.</b>			
9:45-10:45 a.m.	Case-Based Panel	Cutaneous Squamous Cell Carcinoma in the Head and Neck: A Multidisciplinary Case-Based Approach to Treatment	E450b   On Demand
9:45-10:25 a.m.	Otolaryngologist Perspective		Neil Gross, M.D.
10:25-10:45 a.m.	Panel Question and Answer		
9:45-11:15 a.m.	Rapid Oral Abstract Session	Melanoma/Skin Cancers	S406   On Demand
10:45-10:51 a.m.	Abstract 9515: OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.		Rodabe Amaria, M.D.

10:51-10:57 a.m.	Abstract LBA9516: Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).		Adi Diab, M.D.
10:57-11:03 a.m.	Abstract 9517: Efficacy and safety of RP1 combined with nivolumab in patients with anti-PD-1–failed melanoma from the IGRYTE clinical trial.		Michael Wong, M.D.
11:03-11:15 a.m.	Panel Question and Answer		Rodabe Amaria, M.D.; Adi Diab, M.D. and Michael Wong, M.D.
9:45-11:15 a.m.	Clinical Science Symposium	Use of MRD-Guided Strategies to Optimize Therapeutic Interventions	Hall D1   Live Stream
9:45-9:57 a.m.	Minimal Residual Disease Detection and Intervention: Challenges and Opportunities		Scott Kopetz, M.D., Ph.D.
11:01-11:15 a.m.	Panel Question and Answer		
9:45-11:15 a.m.	Rapid Oral Abstract Session	Symptom Science and Palliative Care	S102   On Demand
10:27-10:33 a.m.	Abstract 12017: Technology-enhanced palliative care for patients with advanced cancer undergoing Phase I therapies: A pilot randomized clinical trial (RCT).		David Hui, M.D.
10:33-10:45 a.m.	Panel Question and Answer		
11:30-2:30 p.m.	Oral Abstract Session	Developmental Therapeutics—Immunotherapy	Hall D2   Live Stream
1:38-1:50 p.m.	Abstract 2506: Phase I/II study of the TGF- $\beta$ -trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.		Anthony Conley, M.D.
2:14-2:30 p.m.	Panel Question and Answer		
1:15-2:45 p.m.	Rapid Oral Abstract Session	Gastrointestinal Cancer—Colorectal and Anal	Arie Crown Theater   Live Stream
1:51-1:57 p.m.	Abstract 3515: Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer.		Van Morris, M.D.
2:03-2:15 p.m.	Panel Question and Answer		
1:30-4:30 p.m.	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Lung Cancer—Non-Small Cell Metastatic Prevention, Risk Reduction, and Genetics Symptom Science and Palliative Care	Hall A   On Demand
<b>See the full listing of posters from MD Anderson starting on page 6.</b>			
3-4:15 p.m.	Education Session	Advancing Equity in Global Cancer Outcomes: Strategies for Diverse Population Screening and Early Detection	E450a   On Demand
3:30-3:45 p.m.	Cervical Cancer Screening: A Global Perspective		Kathleen Schmeler, M.D.
3:45-4:15 p.m.	Panel Question and Answer		
3-6 p.m.	Oral Abstract Session	Sarcoma	S100bc   Live Stream
	Chair/Moderator		Ashleigh Guadagnolo, M.D.
5:36-5:48 p.m.	Rational Drug Design: Understanding Your Target		Richard Gorlick, M.D.
5:48-6 p.m.	Panel Question and Answer		
3-6 p.m.	Oral Abstract Session	Hematologic Malignancies—Plasma Cell Dyscrasia	Hall D1   Live Stream
	Chair/Moderator		Hans Lee, M.D.
<b>Tuesday, June 4</b>			
8-9:15 a.m.	Education Session	Optimizing Bispecific Therapy Use in Lymphoma and Multiple Myeloma	S102   On Demand
8:15-8:30 a.m.	New Agents on the Horizon: Targets Other Than CD3/CD20, New Constructs and Trispecifics		Paolo Strati, M.D.
8:45-9:15 a.m.	Panel Question and Answer		
9:45-12:45 a.m.	Oral Abstract Session	Head and Neck Cancer	S100a   On Demand

11:21-11:33 a.m.	Discussion of Abstract 6003: Taking Our Best Shot: Targeting HPV-16		Maura Gillison, M.D., Ph.D.
11:33-11:45 a.m.	Panel Question and Answer		
11:45-11:57 a.m.	Abstract 6006: Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).		Steven Frank, M.D.
12:33-12:45 p.m.	Panel Question and Answer		
9:45-11 a.m.	Education Session		
10:15-10:30 a.m.	Combining DNA Damaging Response Inhibitors with DNA-Damaging Agents		Jennifer Litton, M.D.
9:45-11:15 a.m.	Rapid Oral Abstract Session	Hematologic Malignancies—Plasma Cell Dyscrasia	S102   On Demand
9:45-9:51 a.m.	Abstract 7509: Final results of a Phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).		Sheeba Thomas, M.D.
10:03-10:15 a.m.	Panel Question and Answer		
9:45 a.m.-12:45 p.m.	Rapid Oral Abstract Session	Care Delivery/Models of Care	S100bc   Live Stream
10:21-10:33 a.m.	Finding the Person in Personalized Care Delivery		Lisa Lowenstein, Ph.D.
10:33-10:45 a.m.	Panel Question and Answer		

<b>Posters</b>		
<b>Saturday, June 1   9 a.m.-12 p.m.   Hall A   On Demand</b>		
<b>Poster Board</b>	<b>Care Delivery/Models of Care</b>	
506	Abstract 1635: Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated Phase I department at The University of Texas MD Anderson Cancer Center.	Carlos Torrado, M.D.
<b>Poster Board</b>	<b>Central Nervous System Tumors</b>	
325	Abstract 2026: Radiosurgery to 5 or more newly diagnosed brain metastases in the systemic therapy era.	Thomas Beckham, M.D., Ph.D.
375	Abstract 2076: Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma.	Nazanin Majd, M.D.
385	Abstract 2086: Real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb).	Eric Jonasch, M.D.
389b	Abstract TPS2092: A Phase III randomized controlled trial of post-surgical stereotactic radiotherapy versus surgically targeted radiation therapy with GammaTile for treatment of newly diagnosed metastatic brain tumors.	Thomas Beckham, M.D., Ph.D.
<b>Poster Board</b>	<b>Developmental Therapeutics—Immunotherapy</b>	
23	Abstract 2544: The role of obesity on outcomes of adoptive cellular therapy in solid tumors.	Derrick Tao, M.D.
42	Abstract 2563: Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-17 and pembrolizumab in patients with cold gastrointestinal tumors.	Aung Naing, M.D.
66	Abstract 2587: Recommended Phase II dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).	Sarina Piha-Paul, M.D.
101	Abstract 2622: PERIO-02: Phase Ib pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.	Sunyoung Lee, M.D., Ph.D.
136	Abstract 2657: The impact of proton-pump inhibitor use on the incidence and severity of gastrointestinal toxicity to checkpoint inhibition.	Yinghong Wang, M.D., Ph.D.
139	Abstract 2660: First-line treatment of fecal microbiota transplantation for immune-mediated colitis.	Krishnavathana Varatharajalu, M.D.
140	Abstract 2661: Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.	Yinghong Wang, M.D., Ph.D.

154b	Abstract TPS2681: DUET-01: A first-in-human, Phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors.	Ecaterina Elena Dumbrava, M.D.
159a	Abstract TPS2691: A first-in-human Phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM).	Siqing Fu, M.D., Ph.D.
Poster Board	<b>Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology</b>	
184	Abstract 3039: Comparison of primary versus metastatic tumor tissue sources when designing panels for whole genome-based tumor-informed ctDNA assays in clear cell renal cell carcinoma.	Aaron Seo, M.D., Ph.D.
189	Abstract 3044: Presence of molecular residual disease after pathologic complete response among patients with inflammatory breast cancer.	Jennifer Chen, M.D.
236	Abstract 3091: Phase Ib portion of the ACTION-1 Phase Ib/III trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.	Daniel Halperin, M.D.
244	Abstract 3099: Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors.	Mohamed Gouda, M.D.
252	Abstract 3107: Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.	Sarina Piha-Paul, M.D.
276	Abstract 3131: Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.	Jordi Rodon Ahnert, M.D., Ph.D.
287	Abstract 3142: Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.	Funda Meric-Bernstam, M.D.
292	Abstract 3147: The immunological milieu of oropharyngeal squamous cell carcinoma (OPC) according to HPV and smoking status and its influence on prognosis.	Luana Guimaraes de Sousa, M.D.
297	Abstract 3152: A Phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.	Mohamed Gouda, M.D.
298	Abstract 3153: Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center.	Apostolia Tsimberidou, M.D., Ph.D.,
313a	Abstract TPS3176: A first-in-human, Phase I study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors.	Ecaterina Elena Dumbrava, M.D.
316a	Abstract TPS3182: A Phase I study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449).	Carlos Torrado, M.D.
<b>Saturday, June 1   1:30-4:30 p.m.   Hall A   On Demand</b>		
Poster Board	<b>Gastrointestinal Cancer—Colorectal and Anal</b>	
208	Abstract 3545: Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort.	Madhulika Eluri, M.D.
220	Abstract LBA3557: A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D.	Kanwal Raghav, M.D., M.B.B.S.
275	Abstract 3612: Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer.	Michael LaPelusa, M.D.
286	Abstract 3623: A Phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program.	Andrew Pellatt, M.D.
296a	Abstract TPS3636: Phase II randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.	Kanwal Raghav, M.D., M.B.B.S.
298a	Abstract TPS3640: SWOG S2107: Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.	Van Morris, M.D.
298b	Abstract TPS3641: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.	Arvind Dasari, M.D.
Poster Board	<b>Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary</b>	

47	Abstract 4067: Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma.	Mariela Blum Murphy, M.D.
71	Abstract 4091: Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the Phase 2b HERIZON-BTC-01 study.	Shubham Pant, M.D., M.B.B.S.
101	Abstract 4121: Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.	Shubham Pant, M.D., M.B.B.S.
138	Abstract 4158: Clinical utility and outcomes associated with mutations detection in liquid biopsy for patients with pancreatic ductal adenocarcinoma: Real-world data evidence from a single institution.	Dan Zhao, M.D., Ph.D.
177b	Abstract TPS4215: A Phase I/II study of intraperitoneal (IP) paclitaxel (PTX) in patients with metastatic appendiceal adenocarcinoma.	John Paul Shen, M.D.
Poster Board	Melanoma/Skin Cancers	
308	Abstract 9524: Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.	Hussein Tawbi, M.D.
313	Abstract 9529: Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).	Alexandra Ikeguchi, M.D.
337	Abstract 9553: Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis.	Bilal Anouti, M.D.
342	Abstract 9558: The DIET study: A randomized controlled trial of a high fiber diet intervention (HFDI) in patients (pts) with melanoma receiving immune checkpoint blockade (ICB).	Yan Jiang, Ph.D.
347	Abstract 9563: Analyzing the gut microbiome in adolescent and young adult patients with melanoma receiving immune checkpoint blockade.	Faraz Afridi, M.D.
348	Abstract 9564: Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404.	Michael LaPelusa, M.D.
365	Abstract 9581: Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT).	Michael Davies, M.D., Ph.D.
371	Abstract 9587: Abstract Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma.	Elizabeth Burton
Poster Board	Pediatric Oncology	
406	Abstract 10039: Harmonizing cancer care delivery for AYAs with osteosarcoma: Comparison of pediatric and medical oncology approaches in a single center.	Ariel Nash, M.D.
Poster Board	Sarcoma	
472	Abstract 11546: Immune infiltrate analysis to reveal distinct immune classes for leiomyosarcomas.	Alicia Gingrich, M.D.
512a	Abstract TPS11586: A first-in-human Phase I trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma.	Andrew Livingston, M.D.
<b>Sunday, June 2   9 a.m.-12 p.m.   Hall A   On Demand</b>		
Poster Board	Breast Cancer—Local/Regional/Adjuvant	
194	Abstract 602: Trends, patterns, and outcomes of neoadjuvant chemotherapy (NACT) use among patients with early invasive triple negative breast cancer (TNBC).	Inimfon Jackson, M.D., Ph.D.
Poster Board	Breast Cancer—Metastatic	
22	Abstract 1044: The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast.	Jason Mouabbi, M.D.
77	Abstract 1099: Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab.	Athira Jayan, M.D.
99b	Abstract TPS1123: ACE-BREAST-03: A Phase II trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast	Debu Tripathy, M.D.



	cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).	
Poster Board	Genitourinary Cancer—Kidney and Bladder	
237	Abstract 4542: A Phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).	Nazli Dizman, M.D.
245	Abstract 4550: Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).	Nazli Dizman, M.D.
273	Abstract 4578: FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).	Arlene Siefker-Radtke, M.D.
300	Abstract 4605: Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO).	Mohammad Jad Moussa, M.D.
303b	Abstract TPS4610: Phase Ib/II study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.	Eric Jonasch, M.D.
Poster Board	Genitourinary Cancer—Prostate, Testicular, and Penile	
524b	Abstract TPS5130: Randomized PROSTATE-IQ trial to reduce ADT treatment burden for patients with biochemical recurrence after prostatectomy.	Karen Hoffman, M.D.
Poster Board	Head and Neck Cancer	
340	Abstract 6037: Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02).	Funda Meric-Bernstam, M.D.
381	Abstract 6065: Development and validation of an assay to quantify plasma cell-free human papillomavirus DNA for 13 high-risk types that cause 98% of HPV-positive cancers.	Michael Wotman, M.D.
411	Abstract 6095: Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).	Maria Cabanillas, M.D.
422	Abstract 6106: Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma.	Sarah Hamidi, M.D.
427	Abstract 6111: Efficacy of cytotoxic chemotherapy in recurrent/metastatic adenoid cystic carcinoma (ACC).	Michael Wotman, M.D.
428	Abstract 6112: Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the Phase I study.	Samer Srour, M.B.Ch.B.
<b>Monday, June 3   9 a.m.-12 p.m.   Hall A   On Demand</b>		
Poster Board	Gynecologic Cancer	
419	Abstract 5548: Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer.	Mostafa Eyada, M.D.
444	Abstract 5573: Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.	Nicole Fleming, M.D.
445	Abstract 5574: Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer.	Larissa Meyer, M.D.
492b	Abstract TPS5622: Triage of advanced cervical cancer through immunotherapy induction (TRACTION).	Jeffrey How, M.D.
494b	Abstract TPS5626: Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.	Anne Knisely, M.D.
498a	Abstract TPS5633: A Phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC).	Amir Jazaeri, M.D.
Poster Board	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft	
78	Abstract 6519: FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.	Hall A   On Demand Wei Ying Jen
92	Abstract 6533: In-depth analysis of responders in the Phase III PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.	Elias Jabbour, M.D.

97	Abstract 6538: Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.	Samuel Urrutia, M.D.
106	Abstract 6547: Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.	Eitan Kugler, M.D., Ph.D.
108	Abstract 6549: A Phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).	Mahesh Swaminathan, M.D.
126	Abstract 6567: Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes.	Samuel Urrutia, M.D.
129	Abstract 6570: A Phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.	Kelly Chien, M.D.
131	Abstract 6572: Long term follow-up results of Phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).	Sankalp Arora, M.D.
139	Abstract 6580: A Phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.	Lucia Masarova, M.D.
143	Abstract 6584: Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis.	Julie Braish
144a	Abstract TPS6585: A Phase Ib/2 study of pivekimab sunirine (PVEK, IMG632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.	Naval Daver, M.D.
144b	Abstract TPS6586: A first-in-human Phase I, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).	Naval Daver, M.D.
147a	Abstract TPS6591: Phase Ib trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies.	Guillermo Garcia-Manero, M.D.
Poster Board	Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	
56	Abstract 7073: Survival outcomes after autologous stem cell transplantation in T follicular helper type lymphoma.	Anath Lionel, Ph.D.
Poster Board	Hematologic Malignancies—Plasma Cell Dyscrasia	
156	Abstract 7519: BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.	Mahmoud Gaballa, M.D.
Poster Board	Quality Care/Health Services Research	
231	Abstract 11036: Impact of boarding time on in-hospital mortality in patients with cancer presenting to the emergency department.	Patricia Brock, M.D.
287	Abstract 11092: Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.	Kerin Adelson, M.D.
<b>Monday, June 3   1 p.m.-4:30 p.m.   Hall A   On Demand</b>		
Poster Board	Lung Cancer—Non-Small Cell Metastatic	
413	Abstract 8549: Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer.	Natalie Vokes, M.D.
488	Abstract 8624: A Phase Ib study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).	Kyle Concannon, M.D.
502	Abstract 8638: PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.	Lingzhi Hong, M.D.
512b	Abstract TPS8649: SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.	Marcelo Negrao, M.D.
513b	Abstract TPS8651: Krascendo-170 Lung: A Phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC).	Ferdinandos Skoulidis, M.D., Ph.D.

515b	Abstract TPS8655: TRITON: Phase IIIb study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.	Ferdinandos Skoulidis, M.D., Ph.D.
521a	Abstract TPS8666: FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).	Xiuning Le, M.D., Ph.D.
Poster Board	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	
322	Abstract 8070: The impact of HIV and CD4 count stratification on all cause mortality for adenocarcinoma and squamous cell lung cancers in the antiretroviral therapy era: Analysis of National Veterans Affairs and Kaiser Permanente Northern cohorts.	Elizabeth Chiao, M.D.
350	Abstract 8088: Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes.	Carl Gay, M.D., Ph.D.
372	Abstract 8110: S1701: A randomized Phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.	Anne Tsao, M.D.
Poster Board	Prevention, Risk Reduction, and Genetics	
82	Abstract 10555: Utility of colposcopy for the screening and management of cervical cancer in Africa: A cross-sectional analysis of providers' training and practices.	Joel Fokom Domgue, M.D.
107	Abstract 10580: Evaluating genetic features and clinical characteristics of young women diagnosed with breast cancer by the age of 35.	Christine Kurian, M.D.
122	Abstract 10595: The genetic risk architecture of mucosal melanoma.	Afsaneh Amouzegar, M.D.
145	Abstract 10618: Large cohort analysis of incidental CDH1 PVs among patients undergoing MGPT.	Hiam Abdel-Salam
Poster Board	Symptom Science and Palliative Care	
179	Abstract 12050: Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.	Sriram Yennu, M.D.
183	Abstract 12054: Attitudes and beliefs regarding sexual dysfunction among patients with advanced cancer receiving palliative care.	Patricia Bramati, M.D.
206	Abstract 12077: Abuse potential and analgesic efficacy of different IV opioid infusion rates among patients hospitalized with cancer pain: A randomized crossover trial.	Joseph Arthur, M.D.
213	Abstract 12084: Patient-reported symptom interference with activity- and mood-related functioning prior to start of an early-phase oncology combination trial including immune checkpoint blockade.	Goldy George, Ph.D.
246	Abstract 12117: Patterns of immune-related adverse events (irAEs) in adolescent and young adult (AYA) patients with melanoma receiving immune checkpoint inhibitors (ICIs).	Jiasen He, M.D.